COMPANY OVERVIEW August 18, 2025 1 Disclaimer This presentation and the accompanying oral presentation contain "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our business plans and objectives, potential growth opportunities, competitive position, industry environme ...

Financial Performance - Q4 2025 Remaining Performance Obligation (RPO) reached $158 billion, a 24% year-over-year increase[11] - Next-Generation Security Annual Recurring Revenue (NGS ARR) for Q4 2025 was $558 billion, up 32% year-over-year[11] - Q4 2025 revenue totaled $254 billion, representing a 16% year-over-year growth[11] - The company's FY 2025 adjusted free cash flow was $351 billion, a 12% increase year-over-year, with an adjusted free cash flow margin of 380%[11] - FY 2025 non-GAAP operating margin was 288%, a 150 basis point increase year-over-year, and non-GAAP EPS was $334, up 18% year-over-year[11] Platformization and Customer Growth - The company has approximately 1,400 total platformizations[14] - Platformized customers exhibit a net retention rate (NRR) of 120%[14] - The number of customers with over $5 million in NGS ARR increased by 51% year-over-year, reaching 156, while those with over $10 million in NGS ARR increased by 50% year-over-year, totaling 51[18] Network Security and SASE - Network Security NGS ARR reached $39 billion, growing approximately 35% year-over-year[21] - SASE ARR grew by 35% year-over-year[23] - The company has approximately 6,350 SASE customers, an 18% increase year-over-year[23] Cortex and Security Operations - Total Cortex & Prisma Cloud ARR is approximately $17 billion, up approximately 25% year-over-year[24] - The company has approximately 400 XSIAM customers, more than double year-over-year[25]

2 3 3 2Q25 Gross Profit and Gross Margin were impacted by $6.4 million in non-cash charges related to obsolete inventory adjustments and write-down of capitalized costs related to incomplete projects $8.0 $8.8 $9.8 $10.6 $11.8 $- $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 2Q24 3Q24 4Q24 1Q25 2Q25 $ in millions Over Last 5 Quarters 5 Repeat and Recurring Service Revenue All comparisons are Q2 -2025 year-over-year, unless otherwise noted Service Revenues consist of repeat charging service revenues, recurring network fee ...

Roadshow presentation 9M 2024/25 Making life easier Strive25: Sustainable Growth Leadership Fikria , User, Continence Care Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements are based on Coloplast's current expectations, estimates and assumptions and based on the ...

Results 2Q25 Transf rming lives with our energy Disclaimer Certain statements and estimates in this material may represent expectations about future events or results which are subject to risks and uncertainties that may be known or unknown. There is no guarantee that events or results will occur as referred to in these expectations. These expectations are based on the present assumptions and analyses from the point of view of our management, in accordance with their experience and other factors such as the ...

Q2 2025 Highlights - Transactions reached 397,000, a 26% year-over-year growth[26] - The company achieved record revenue of $74 million, a 31% year-over-year increase[26] - The platform has expanded to include 75 carriers[26] Financial Performance - Q2 2025 revenue was $74 million, exceeding the guidance of $70 million - $71 million[55] - Adjusted EBITDA for Q2 2025 was $(29) million, aligning with the guidance of $(29) million - $(28) million[55] - Non-IFRS gross margin reached 735% for Q2 2025, compared to 720% in Q2 2024[75] Guidance - Q3 2025 transaction guidance is 419,000 - 425,000, representing a 24%-25% year-over-year growth[69] - Q3 2025 revenue is projected to be $76 million - $77 million, a 23%-25% year-over-year increase[69] - Full year 2025 revenue guidance is $295 million - $300 million, reflecting a 24%-26% year-over-year growth[69] - Full year 2025 Adjusted EBITDA is expected to be $(109) million - $(105) million[69]

Tonmya Approval and Launch - TonmyaTM is the first FDA-approved medicine for fibromyalgia in over 15 years[1,13] - Tonix is well-positioned to support the commercial launch of TonmyaTM, expected in Q4 2025[13] - Tonix ended Q2 2025 with approximately $125 million in cash and cash equivalents and raised approximately $50 million in Q3 2025 through equity sales[41] - The company anticipates its cash runway will support the launch and other operations into Q3 2026[13,41] Clinical Efficacy and Safety - Clinical trials demonstrated durable reduction in fibromyalgia pain with TonmyaTM[22] - In Trial 1, the TONMYA group showed a change from baseline of -1.9 compared to -1.5 in the placebo group, with a p-value of 0.010[28] - In Trial 3, the TONMYA group showed a change from baseline of -1.8 compared to -1.2 in the placebo group, with a p-value of less than 0.001[29] - A greater percentage of study participants taking Tonmya experienced a clinically meaningful (≥30%) improvement in their pain after three months, compared to placebo[35] - The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer[24,40,94] Market Opportunity and Commercial Strategy - Over 10 million people in the US are living with fibromyalgia[13,50] - Approximately 5% of fibromyalgia-diagnosing HCPs write approximately 70% of fibromyalgia prescriptions[62]

Financial Performance - Q2 2025 revenue reached $811 million, a 3% year-over-year increase[50, 55] - H1 2025 revenue totaled $163447 million, a 5% year-over-year increase[55, 89] - Q2 2025 Adjusted EBITDA was $21 million[50, 57] - The company repurchased 49 million shares for $233 million in Q2 2025[58, 65] - The company has approximately $85 million remaining for share repurchases as of August 15, 2025[58, 65] Market Position and Growth - Riskified reviewed approximately $145 billion in GMV in the twelve months ended June 30, 2025[16, 18] - The company estimates the global ecommerce GMV to be approximately $65 trillion in 2025 and $83 trillion in 2029[19] - Non-GAAP operating expenses as a percentage of revenue decreased from 50% to 47% year-over-year[56] Future Outlook - The company's 2025 revenue guidance is between $336 million and $346 million[59] - The company's 2025 Adjusted EBITDA guidance is between $18 million and $26 million[59] - The company expects approximately $30 million in Free Cash Flow in 2025[74]

Company Overview and Milestones - CBAK was among the first to research lithium battery applications in cars, positioning itself as a pioneer in the EV era[9] - Model 32140 cells captured 19% of the global market share, while Model 26650 captured 64% of the global market share in 2024[12] - Nanjing Branch reported a net income of RMB 2846 million with a gross margin of 2751% for the first 6 months of 2025[13] Production Capacity and Expansion - Dalian Branch's production capacity is expected to reach 33 GWh by 2025, mainly for Model 40135 cells[19] - Nanjing Branch has two production lines with a capacity of 13 GWh for lithium-ion batteries, or 06 GWh with one line for lithium-ion batteries and 048 GWh with the other line for sodium-ion batteries[24] - CBAK is planning to expand Nanjing Branch's capacity up to 20 GWh once fully constructed[24] Product Portfolio and Development - Model 40135 is about 5 times the capacity of Model 26650, 15% higher in energy density and 12% lower in cost[37] - Model 32140 sales volume captured 19% of global market share, Model 26650 for 64% of global market share[12] Financial Performance and Projections - Net revenues from battery business in the first half of 2025 totaled $7546 million, with residential energy supply & uninterruptable supplies accounting for 4704%[49] - Sales forecast for the battery segment in 2025 is projected to reach RMB 14 billion, a 4098% increase over 2024[69] - Net income for the battery segment is projected to reach RMB 100 million in 2025[70]

Financial Performance - Q2 2025 revenue reached $155.6 million[9], compared to $99.2 million[9] in Q2 2024, representing a significant increase - Adjusted EBITDA for Q2 2025 was $17.3 million[11], while Q2 2024 saw $23.5 million[11] - The company reported a net loss after tax of $147.7 million[12] for Q2 2025 - Cash and cash equivalents totaled $299.8 million[12], with crypto holdings of $169.3 million[12] Operational Highlights - SEALMINER A2 sales generated $69.5 million[12] in revenue - 21.2 EH/s of SEALMINER A2 mining rigs have been manufactured, with an additional 0.4 EH/s in final assembly as of the end of July 2025[13] - Self-mining hash rate increased from 11.5 EH/s in March 2025 to 16.5 EH/s in June 2025[15] - Hash rate of mining rigs sold increased ~17x, from 0.3 EH/s in Q1 2025 to 5.0 EH/s in Q2 2025[17] Future Growth & Capacity - The company has 1.3 GW of existing power capacity and a secured 2.7 GW pipeline[35] - Potential ASIC Revenue TAM is estimated at ~$21.25 billion[24] - Potential SEALMINER Revenue at 30% market share is estimated at ~$6.4 billion[26]